Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical hold.

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter of Fiscal Year ...

Amgen posted 11% revenue growth in the fourth quarter, with at least double-digit growth from ten products. The biotechnology company on Tuesday reported a profit of $627 million, or $1.16 a share ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

These products underscore Amgen's capacity to seize growth opportunities, particularly in rare disease markets. Additionally, the operating margin expanded to 26.5%, reflecting operational ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, despite facing market challenges.